Integrate the Patient Voice to Develop Safer & More Effective Gene Therapies That Are Meaningful to Patients

As investment in gene therapies continues to grow rapidly, more effectively engaging patients throughout development has become a priority for any company serious about building safer and more meaningful gene therapy programs.

In this context, the 2nd Annual Gene Therapy Patient Engagement Summit will unite patient advocacy and engagement leaders from gene therapy and gene editing drug developers, patient groups and patients themselves to address the specific challenges of genetic therapy patient engagement, generating actionable insights through detailed case studies and open, honest discussions.

Join us to hear directly from companies and institutions including Spark Therapeutics, Ultragenyx, FDA, Global Genes, and CRISPR Therapeutics on key topics including managing expectations across gene therapy development, navigating patient input on one-time transformative treatments with novel clinical trial designs combined with extensive follow-ups, and developing educational materials on gene therapy to raise awareness in collaboration with patient advocacy organizations. Leverage their knowledge and experiences to ultimately ensure effective creation and implementation of patient-centric gene therapy programs.

 

Attendees of the Gene
Therapy Event Series have said:

"I found the presenters and participant patient engagement knowledge superb, as was their willingness to share."

4D Molecular Therapeutics

“Lots of useful information and good variety of perspectives.”

Ten Bridge

“Exciting new way of participating in scientific conference and discussion.”

uniQure

“Incredibly positive and eye-opening experience for a scientist new to the field.”

Novartis Gene Therapies

2022 Expert Speakers Include

Amy Fisher

Head of Patient Advocacy

Spark Therapeutics

Edgar Vega

Senior Manager, Patient Advocacy

uniQure

Kristen Huehbner

Associate Director, Global Patient Advocacy & Engagement

BioMarin

PJ Brooks

Deputy Director, Officer of Rare Diseases Research

NIH

Safiyya Gassman

Senior Director, Policy & Public Affairs

Pfizer

Other Events In The Gene Therapy Series